Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 in the Treatment of Patients With Recurrent/Progressive Non-small Cell Lung Cancer
Latest Information Update: 11 Dec 2025
At a glance
- Drugs BioTTT 001 (Primary)
- Indications Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 11 Dec 2025 New trial record